A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil®) by Govan, Vandana A
© 2008 Dove Medical Press Limited.   All rights reserved
Therapeutics and Clinical Risk Management 2008:4(1) 65–70 65
REVIEW
A novel vaccine for cervical cancer: quadrivalent 
human papillomavirus (types 6, 11, 16 and 18) 
recombinant vaccine (Gardasil®)
Vandana A Govan
Division of Medical Virology, 
Department of Clinical Laboratory 
Sciences and Institute of Infectious 
Diseases and Molecular Medicine, 
Faculty of Health Sciences, University 
of Cape Town, Observatory, Cape 
Town, South Africa
Correspondence:   Vandana A Govan 
Room S3.26.1 Wernher and Beit South 
Wing,Institute of Infectious Diseases and 
Molecular Medicine, Faculty of Health 
Sciences University of Cape Town, 
Medical School, Observatory, Cape Town 
South Africa
Tel +27 21 4066366
Fax +27 21 4066681
Email vandana.govan@uct.ac.za
Abstract: Human papillomaviruses (HPVs) are one of the most common sexually transmitted 
infections and remains a public health problem worldwide. There is strong evidence that HPV 
causes cervical, vulva and vaginal cancers, genital warts and recurrent respiratory papillomatosis. 
The current treatments for HPV-induced infections are ineffective and recurrence is common-
place. Therefore, to reduce the burden of HPV-induced infections, several studies have inves-
tigated the efﬁ  cacy of different prophylactic vaccines in clinical human trials directed against 
HPV types 6, 11, 16, or 18. Notably, these HPV types contribute to a signiﬁ  cant proportion of 
disease worldwide. This review will focus on the published results of Merck & Co’s prophy-
lactic quadrivalent recombinant vaccine targeting HPV types 6, 11, 16, and 18 (referred to as 
Gardasil®). Data from the Phase III trial demonstrated that Gardasil was 100% efﬁ  cacious in 
preventing precancerous lesions of the cervix, vulva, and vagina and effective against genital 
warts. Due to the success of these human clinical trials, the FDA approved the registration of 
Gardasil on the 8 June 2006. In addition, since Gardasil has been efﬁ  cacious for 5 years post 
vaccination, the longest evaluation of an HPV vaccine, it is expected to reduce the incidence 
of these type speciﬁ  c HPV-induced diseases in the future.
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Introduction
Papillomaviruses (PVs) are DNA tumor viruses and infect squamous or mucosal 
epithelia (Stanely 2003). To date, there are over 100 different human PV (HPV) 
genotypes that have been fully sequenced and can be divided into low-risk, non-
oncogenic, or high-risk oncogenic types (de Villiers et al 2004; Bernard 2005) by their 
viral ability to cause malignant disease (Munoz et al 2003) (Table 1). The predominant 
low-risk types are HPV 6 and 11 and cause 90% of genital warts (condyloma acuminata) 
while HPV 16 and 18 are the most prevalent high-risk types, causing 70% of cervical 
cancer and cervical intra-epithelial neoplasia (CIN) (de Villiers et al 2004) and are 
considered to be the most destructive oncogenic viruses worldwide. Globally, the 
incidence and mortality rates of new cases, caused by HPV-related cervical cancer 
were estimated to be approximately 500,000 in 2002 (Ferlay et al 2004). In addition, 
it is estimated that sexually active men and women have a 50% lifetime risk of HPV 
infection (WHO 2004).
Interestingly, although the prevalence of HPV DNA among most sexually active 
women in the general population is high, these infections are generally transient and 
infected individuals are able to eliminate the virus without intervention and do not 
develop cancer (Koutsky 1997). Thus an effective host immune response and the 
genetic make-up of the individual may be an important determinant for the persistence 
and progression of HPV induced cervical cancer (Magnusson and Gyllensten 2000). Therapeutics and Clinical Risk Management 2008:4(1) 66
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Consequently, several studies have investigated genetic host 
factors and immune responses, to describe the association 
between genital HPV infection and cervical cancer (Stanczuk 
et al 2001; Deshpande et al 2005; Govan et al 2005). 
Although these investigations have not elucidated the role 
of a few genetic host factors for the development of cervical 
cancer these studies emphasize the possible variability of 
genetic host factors and ethnic disparity in diverse popula-
tion groups and should thus, not be viewed in isolation as 
other confounding factors may contribute to the progression 
of disease (Govan et al 2003).
Current therapies for HPV-related 
disease
Up until now the current approaches for the treatment 
and control of HPV-related infections have been variable. 
Although condoms may afford some protection, infection 
by HPV types may still occur via the unprotected areas of 
the genital skin (Burchell et al 2006). In addition, despite 
the widely adopted and effective cervical cytology screening 
test, Papanicolaou (Pap) smear, the incidence of new HPV-
induced infections remains a global public health problem, 
particularly in developing countries where cervical cancer is 
the most common cancer among women (WHO 2004). The 
main contributing factors that are responsible for this health 
problem in several countries is due to the lack of established 
and stringent routine screening programs and even in 
developed nations the disadvantaged minorities may not have 
access to cervical cancer screening (Roden and Wu 2006). 
Furthermore, the accepted treatments for HPV-related disease 
are limited, uncomfortable, invasive, costly and inefﬁ  cient 
with a high relapse rate (Robinson 2001). Therefore, a 
preventative treatment approach such as the development of a 
prophylactic vaccine would be the most cost effective means 
to reduce the incidence of HPV-related infections.
Biology of PV
When selecting vaccine targets an understanding of the 
molecular pathogenesis of PV-associated infections is 
central, as PVs are able to evade the host immune system 
in the early stages of carcinogenesis. The lifecycles of PVs 
are linked to the differentiation stages of the host epithelial 
cells, and replication is restricted exclusively to the stratiﬁ  ed 
squamous epithelium (Frazer 2004). PVs are small, non-
enveloped viruses containing a 8kb double-stranded closed 
circular DNA genome, encoding six early proteins (E1, E2, 
E4, E5, E6 and E7), two late proteins (L1 and L2) and a 
non-coding regulatory region, the long-control region (LCR) 
(zur Hausen 2000). The general organization of the HPV 
genome is shown in Figure 1. The early genes contribute to 
transformation and viral replication, the late genes provide 
capsid proteins and the LCR contains the origin of replica-
tion (zur Hausen 2000).
Rationale for a preventative vaccine
As PVs are host and tissue speciﬁ  c, several animal PV 
models have been developed and have provided signiﬁ  -
cant information for vaccine development. In particular, 
preclinical studies using the cottontail rabbit papilloma-
virus (CRPV) in rabbits, bovine papillomavirus (BPV) 
in cattle and canine oral papillomavirus (COPV) in dogs 
have successfully provided a better understanding of the 
molecular mechanism that regulate normal cell growth, 
steps involved in cancerous cell changes (Frazer 2004) 
and have tested the potential of different delivery systems 
(Breitburd et al 1995; Jansen et al 1995; Brandsma et al 
2004; Govan et al 2006).
Table 1 The major high- and low-risk HPV types
Classiﬁ  cation  HPV types
High-risk types  16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82
Low-risk types  6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, CP6108
Potentially high-risk  26, 53, 66
01234 56 7 8kbp
E6 E2 L1 LCR
E7 E1 E4 E5 L2
Figure 1 A linearized general organization of the HPV 16 genome (7.905 base pairs) showing the long control region (LCR), the early (E), and late (L) genes.Therapeutics and Clinical Risk Management 2008:4(1) 67
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It has been shown that the expression of PV L1 genes 
in vitro results in the assembly of virus-like particles 
(VLPs) and induces high titers of virus-neutralizing serum 
antibodies when administered as an immunogen (Hines et al 
1994; Christensen et al 1994). Although VLPs are morpho-
logically and antigenically almost indistinguishable from 
the native HPV virion, they are non-infectious, lack viral 
DNA, and most importantly they are highly immunogenic 
and afford protection from papillomavirus challenge. Due 
to the encouraging animal studies, efforts to produce a 
vaccine against HPV-induced infections were centered on 
the major capsid protein, L1 VLPs and were translated into 
human phase I clinical trials.
Efﬁ  cacy trials
In a placebo-controlled human clinical trial, women who 
were HPV 16 negative, at the time of vaccination, were 
protected 17.4 months post HPV 16 L1 VLP vaccination 
from the development of CIN (Koutsky et al 2002). 
This yeast produced HPV 16 VLP vaccine was 100% 
efﬁ  cacious in the prevention of HPV16-induced infection. 
Consequently, following on the successful human clinical 
trials, two pharmaceuticals companies, GlaxoSmithKline 
(GSK) and Merck & Co developed bivalent and quadrivalent 
HPV-VLP L1 vaccines respectively. GSK assessed the 
efﬁ  cacy of a bivalent HPV16/18 VLP vaccine. The L1 
protein of each type was expressed via a recombinant 
baculovirus vector where the resulting VLPs were 
combined to produce the vaccine, CervarixTM. Cervarix 
has been shown to be efﬁ  cacious through 4.5 years, highly 
immnuonogenic and safe, and there is evidence of cross-
protection against incident infection with HPV types 31 
and 45 (Harper et al 2006). The quadrivalent vaccine by 
Merck and Co was prepared in a yeast system and the 
expressed L1 protein of each type was combined to generate 
Gardasil®. To date, Gardasil has been shown to be highly 
effective trough 5 years in the prevention of HPV induced 
disease (Villa et al 2006). The description and composition 
of Cervarix and Gardasil are tabulated in Table 2. This 
review will focus only on the results generated from the 
clinical trials of Gardasil (manufactured by Merck and 
Co, Inc, Whitehouse Station, New Jersey). The efﬁ  cacy 
data of the randomized, placebo-controlled efﬁ  cacy trials 
of the HPV L1 VLP vaccines are summarized in Table 3 
and the important recommendations stated by the Advisory 
Committee on Immunization Practices (ACIP) are tabulated 
in Table 4.
Drawbacks of the quadrivalent 
vaccine
Type speciﬁ  city
It has been shown in pre-clinical animal challenge models 
(Breitburd et al 1995) and clinical human trials (Koutsky 
et al 2002) that immunization with a type-speciﬁ  c PV L1 
VLP will elicit protection only to the same homologous 
PV type. In addition, it was reported that in a clinical 
human trial, women who were vaccinated against HPV 
16 L1 VLP, a number of women developed CIN lesions 
that were induced by other HPV types other than HPV 
16 (Koutsky et al 2002). However, it should be noted that 
evidence of cross-protection has been shown in Cervarix 
against infection with HPV 31 and HPV 45. Nevertheless, it 
is estimated that the preventative quadrivalent vaccine will 
not provide protection against the almost 30 % of cervical 
Table 2 Description and composition of the bivalent and quadrivalent HPV-L1 vaccines in human clinical trials
 Gardasil® CervarixTM
1. Company  Merck & Co  GlaxoSmithKline
2. Vaccine formulation  VLP derived from HPV 6, 11, 16 and 18  VLPs derived from HPV 16 and 18
3. Composition  Produced in a yeast system  Produced in an insect-cell system
4. Route of administration  Intramuscular  Intramuscular
5. Dose schedule  three-dose regime 0, 2, and 6 months   three-dose regime 0, 1, and 6 months
6. Dosages  0.5 mL (containing 20 µg HPV6,   0.5 mL (containing 20 µg HPV16 and
 40  µg HPV11, 40 µg HPV16 and 20 µg 20  µg HPV18
 HPV18  VLP 
7.   Adjuvant 225  µg of aluminium hydroxyphosphate  50 µg of aluminium hydroxide with 50 µg
 sulphate  (alum)  of  AS04
8. Current analysis of vaccine  Safe, well tolerated and 100% efﬁ  cacious  Safe, well tolerated and 100% efﬁ  cacious
9. Sustained efﬁ  cacy  Effective through 5 yrsa  Effective through 4.5 yrsb
10. Licensed for public use    60 countries  Australia (women  45 yrs)
aVilla et al (2006).
bHarper et al (2006).Therapeutics and Clinical Risk Management 2008:4(1) 68
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cancers that are from types other than HPV-16 /18 (Schiller 
and Nardelli-Haeﬂ  iger, 2006). In addition, this prophylactic 
vaccine will only be effective for those individuals that have 
not been exposed to the high-risk HPV types (Hildesheim 
et al 2007) as the therapeutic potential of the low-risk types 
vaccine have not been established.
One of the current thoughts that may circumvent the 
lack of broad cross-protection is the use of the minor capsid 
protein, L2. Recently several studies have demonstrated that 
L2-based vaccines have broad cross-neutralizing epitopes 
and would thus induce cross-protective immunity to dif-
ferent HPV types (Roden et al 2000; de Jong et al 2002; 
Palmer et al 2006). While L2-based vaccines have broad 
cross-protection, the neutralizing antibody titres generated 
are much lower than the current candidate VLP L1-based 
vaccines. The prophylactic potential of L2 based vaccines 
can possibly be increased by L2 codon optimization or 
generating a L2 peptide-based vaccine. Nevertheless, it is 
suggested that extensive pre-clinical studies should be con-
ducted to elucidate ways of increasing the immunogenicity 
of L2-based vaccines.
Availability of the quadrivalent vaccine 
in developing countries
The cost effectiveness of the current quadrivalent vaccine 
has been examined using the Markov mathematical model 
(Sanders and Taira 2003; Goldie et al 2004; Taira et al 2004). 
This model was used to estimate the cost per quality-adjusted 
life year (QALY) and deliberate on the impact and cost 
of HPV vaccination for a given group, without consider-
ing the effect of vaccination on HPV transmission in the 
population (Goldie et al 2004; Markowitz et al 2007). One 
model estimated that the lifetime risk for cervical cancer 
in the vaccinated group would be reduced by 58% and the 
incidence of cervical cancer would be reduced by 20% com-
pared with no vaccination (Goldie et al 2004). However, as 
these models have been estimated for developed countries 
where vaccination coverage would probably be 70%–100%, 
widespread distribution of the vaccine will not be achieved 
in developing countries where the vaccines are needed most. 
Given that the burden of cervical cancer in most developing 
countries is attributed to poverty, lack of education, lack of 
effective screening programs, lack of resources (human and 
ﬁ  nancial) and infrastructure (Denny et al 2006), widespread 
distribution of the vaccine will not be successful. In addi-
tion, the vaccines would need proper cold chain for storage 
as the route of administration is intramuscular making it 
too expensive to distribute in low-resource settings. It is 
suggested that funding sources and commercial companies 
should provide or assist the low-resource communities with 
ﬁ  nancial and perhaps human resources for the distribution 
of the prophylactic vaccine in conjunction with a routine 
screening program for cervical disease.
Public health burden in developing 
countries
A further signiﬁ  cant health problem in developing countries 
is infection with the human immunodeﬁ  ciency virus (HIV). 
In sub-saharan Africa the epidemic has grown exponentially 
over the past 15 years making it the worst HIV epidemic in 
Table 3 Summary of the randomized, human placebo-controlled efﬁ  cacy trials of Gardasil®
VLP vaccine  Vaccine/placebo  Vaccine schedule  Duration of trial  Vaccine efﬁ  cacy (HPV vaccine
  group    (months)  type) % (95% CI)
HPV 16a  765/768  0, 2, 6  17  100 (90–100)
HPV 6/11/16/18b  277/275  0, 2, 6  35  89 (70–97)
HPV 6/11/16/18c  104/120  0, 2, 6  60  95 (69–100)
aKoutsky et al (2002).
bVilla et al (2005).
cVilla et al (2006).
Table 4 Selected recommendations by ACIPa for the use 
of Gardasil® following on from its licensure
Vaccination program  Recommendations
1. Route of administration  Intramuscular
2. Dose schedule  Three-dose regime
  (0, 2, and 6 months)
3. Age of females   b9, 11–12 yrs
at vaccination
4. Catch-up age at vaccination  c13–26 yrs
5. Post-vaccination  Routine cervical cancer 
  screening is compulsory
6.   Vaccination of males  Not recommended (the efﬁ  cacy
  data are not yet available)
7. Groups not included in program  Females  26 yrs (data not yet
 available)
 Females   9 yrs
aACIP – Advisory Committee on Immunization Practices (Markowitz et al 2007).
bIt is recommended that females as young as 9 years can be vaccinated.
cThese are females that have not been previously vaccinated.Therapeutics and Clinical Risk Management 2008:4(1) 69
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the world (Department of health of South Africa 2005) and 
the availability of antiretroviral therapies are limited. In 
addition, it has been reported that HIV positive women are 
at an increased risk of developing cervical squamous intra-
epithelial lesions (SIL) and cervical cancer (La Ruche et al 
1998; Sitas et al 2000). Moreover, cervical cancer is included 
as one of the deﬁ  ning conditions of the acquired immune 
deﬁ  ciency syndrome (AIDS) (Centers for Disease Control 
and Prevention 1993). Thus, this health problem would render 
a signiﬁ  cant portion of the sexual active population immu-
nocompromised and will probably render the quadrivalent 
vaccine ineffective.
Therapeutic potential of Gardasil
Recently, in a Phase III community based randomized trial, 
it has been demonstrated that vaccination with a bivalent 
HPV-16/18 L1 VLP vaccine did not induce viral clearance 
in women with existing HPV induced infection (Hildesheim 
et al 2007). However, there are no placebo-controlled human 
trials that show the therapeutic beneﬁ  t of the low-risk HPV 
types vaccines that have been included in Gardasil. For this 
HPV VLP L1 vaccine to afford a positive therapeutic effect, 
a strong cytotoxic T-cell (CTL) response should be elicited. 
However, given that the important stages in the development 
of cervical cancer are, integration of the viral genome into 
the host cell chromosomes and the consistent expression of 
HPV E6 and E7 proteins in cervical cancer cells, the L1 gene 
may be disrupted (Roden and Wu 2006). Therefore, the low 
levels of L1 will not induce a L1-speciﬁ  c CTL response and 
the elimination of established HPV-induced lesions will be 
not be achieved by the VLP L1 quadrivalent vaccine.
However, as discussed above, L2 based vaccines show 
promise as a potential candidate for the next generation of 
prophylactic vaccines. L2 based vaccines have also been 
tested in a therapeutic setting and have provided encourag-
ing results in the CRPV rabbit challenge model (Govan and 
Williamson 2007). It was demonstrated that the regression of 
CRPV-induced papillomas was achieved following immuni-
zation of rabbits with recombinant Bacille Calmette-Guerin 
rBCG expressing CRPVL2 or CRPVL2E7E2 proteins (Govan 
and Williamson 2007). This L2-based vaccine approach is 
promising and warrants further preclinical investigations to 
increase the efﬁ  cacy of a possible combined prophylactic 
and therapeutic candidate vaccine.
Conclusion
The development of the current effective quadrivalent vaccine 
is a major breakthrough in HPV research. Indeed, the vaccine 
will serve to signiﬁ  cantly reduce the burden of HPV related 
anogenital infections in young women worldwide. However, it 
should be clear from this review that this quadrivalent vaccine 
is not the ideal vaccine for developing countries and fervent 
basic scientiﬁ  c research need to continue and build on what 
we already know. For instance, work on L2 needs to continue 
to potentially provide a broad cross-protection and second 
generation HPV vaccine. Issues of vaccine availability and cost 
in the developing countries also need to be addressed with the 
aim being to reduce the global burden of HPV disease rather 
than only in countries that can afford vaccines.
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